John Byrd
约翰·伯德
MD
Chair, Department of Internal Medicine; Director, Division of Hematology内科主任兼血液学部主任
👥Biography 个人简介
Dr. John Byrd is widely regarded as the pioneer of BTK inhibitor therapy in CLL. His foundational work at Ohio State University and subsequent role at the University of Cincinnati established ibrutinib as the first FDA-approved BTK inhibitor for CLL, revolutionizing treatment paradigms.
🧪Research Fields 研究领域
🎓Key Contributions 主要贡献
BTK Inhibitor Discovery and Translation
Conducted the first clinical trials of ibrutinib in CLL, demonstrating unprecedented efficacy and transforming BTK inhibition from concept to approved therapy. His PCYC-1102 study was seminal to ibrutinib's approval.
CLL Biology and Resistance Mechanisms
Elucidated mechanisms of ibrutinib resistance including BTK C481S mutation and downstream pathway reactivation, guiding the development of next-generation irreversible and non-covalent BTK inhibitors.
Representative Works 代表性著作
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
New England Journal of Medicine (2013)
Landmark phase 1b/2 trial demonstrating ibrutinib's remarkable efficacy in relapsed/refractory CLL, establishing BTK as a therapeutic target.
Acalabrutinib versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia
New England Journal of Medicine (2023)
Head-to-head trial showing acalabrutinib's improved cardiac safety profile compared to ibrutinib in CLL patients.
🏆Awards & Recognition 奖项与荣誉
📄Data Sources 数据来源
Last updated: 2026-01-15 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Drew M. Pardoll
Johns Hopkins University
Padmanee Sharma
MD Anderson Cancer Center
Naiyer A. Rizvi
Columbia University Irving Medical Center
关注 约翰·伯德 的研究动态
Follow John Byrd's research updates
留下邮箱，当我们发布与 John Byrd（University of Cincinnati College of Medicine）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment